(firstQuint)Phase 1 Study of ELX-02 in Healthy Adults.

 This is a study in humans of ELX-02, an advanced synthetic aminoglycoside optimized as a translational read-through drug (TRID) for the treatment of genetic conditions caused by nonsense mutations.

 This is a classical Phase 1a study designed as a randomized, double-blinded, placebo-controlled, single dose escalation to evaluate the safety, tolerability and pharmacokinetics of ELX-02 in healthy adult volunteers.

.

 Phase 1 Study of ELX-02 in Healthy Adults@highlight

Phase 1 Single Ascending Dose Study in Normal Healthy Volunteers